Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics

Area of Science:

• Oncology
• Pharmacogenomics
• Molecular Biology

Background:

• Cancer precision medicine seeks to personalize treatment by predicting drug response.
• Genomic mutation analysis has shown limited clinical utility due to a lack of actionable mutations.
• Gene expression signatures offer a promising alternative for predicting patient response to cancer therapies.

Purpose of the Study:

• To investigate the relationship between gene expression levels and drug sensitivity in cancer cell lines.
• To identify potential mechanisms of drug resistance and sensitization based on gene expression patterns.
• To evaluate the efficacy of drugs targeting specific genes in relation to their expression levels.

Main Methods:

• Utilized large-scale datasets from The Genomics of Drug Sensitivity of Cancer (GDSC) and The Cancer Therapeutics Response Portal (CTRP).
• Analyzed correlations between drug sensitivity and the expression of known drug targets across hundreds of cell lines and drugs.
• Identified correlations between drug sensitivity and the expression of non-target genes.

Main Results:

• Drug sensitivity was significantly correlated with the expression of at least one known target for approximately one-third of the drugs analyzed.
• A significant inverse correlation between target gene expression and drug sensitivity was observed for 8% of annotated targets.
• Identified non-target genes associated with drug sensitivity, with literature support for their roles in sensitization and resistance.

Conclusions:

• Gene expression signatures are valuable predictors of cancer drug response.
• Drug-target expression correlations reveal insights into drug efficacy and potential resistance mechanisms.
• The study highlights the complexity of drug response, involving both target and non-target gene interactions.